Hikma Pharmaceuticals Stock
Pros and Cons of Hikma Pharmaceuticals in the next few years
Pros
?
C******** o* t** e**********
?
M***** P*******
?
G***** c******* t* c**********
Cons
?
S********** s********
?
B****
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Hikma Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Hikma Pharmaceuticals | 1.090% | 0.325% | 2.205% | -16.486% | 5.341% | -23.388% | -40.577% |
| Viatris Inc. | -0.010% | -2.141% | 6.492% | 98.526% | 45.743% | 59.506% | 32.134% |
| Opko Health Inc. | -0.890% | -24.832% | -11.111% | 6.870% | 2.733% | -36.951% | -62.264% |
| Repligen Corp. | -0.080% | 1.842% | 6.342% | 26.472% | -7.739% | -16.699% | -39.133% |
Comments
Hikma Pharmaceuticals (OTCMKTS:HKMPF) was downgraded by analysts at Barclays PLC to an "underweight" rating.
Show more
Ratings data for HKMPF provided by MarketBeat
Hikma Pharmaceuticals PLC (OTCMKTS: HKMPF) is now covered by analysts at BNP Paribas. They set an "outperform" rating on the stock.
Show more
Ratings data for HKMPF provided by MarketBeat
